UTHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
UTHR is a good buy for a beginner with a long-term horizon and $50,000-$100,000 to invest. My view is positive because the fundamentals and news flow are supportive, analyst sentiment has improved meaningfully, and there are no strong insider, hedge fund, or political selling signals. The stock is not showing a strong short-term technical breakout right now, but for a long-term investor who is not trying to time the perfect entry, the current setup is attractive enough to buy.
Current price is 546.72, sitting just below the pivot at 557.33 and above support at 539.98. That means the stock is trading in a relatively tight zone near support, not in a strong uptrend right now. MACD histogram is negative at -2.872 and still below zero, which signals weak near-term momentum. RSI_6 at 36.73 is neutral-to-soft and not oversold, while moving averages are converging, suggesting consolidation rather than a trend reversal. The technical picture is mildly cautious short term, but not broken.
Recent news is clearly supportive: TETON study results showed significant lung function improvement in idiopathic pulmonary fibrosis patients, and UTHR is preparing an FDA NDA submission for Tyvaso, which could become the first inhaled anti-fibrotic treatment for IPF. Analysts at multiple firms raised price targets, with Wells Fargo and Raymond James especially constructive. The company is also being held by Renaissance Technologies with nearly 1.8 million shares, which supports institutional confidence. These are strong long-term catalyst signals.
Near-term technical momentum is weak, with MACD negative and price below pivot resistance. The market context is also weak, with the S&P 500 down 1.74% in the provided data. Analyst views are not unanimous, as Morgan Stanley remains Equal Weight and even trimmed its target slightly. Options flow shows elevated put volume, suggesting some hedging or caution. The similar-pattern forecast also suggests a slightly negative one-month return expectation.
No latest quarter financial snapshot was provided, so I cannot assess quarter-over-quarter revenue or earnings growth directly. Based on the available information, the company’s growth narrative is being driven more by pipeline and product expansion than by reported financial metrics in this dataset. The mention of Tyvaso stabilization and potential IPF launch supports a growth-oriented long-term thesis, but the latest quarterly financial season was not provided.
Analyst sentiment has improved overall. Recent ratings include Wells Fargo upgrading UTHR to Overweight with a $735-$738 target, Raymond James initiating Outperform with a $700 target, RBC raising its target to $700 with Outperform, and H.C. Wainwright keeping Buy at $660. Morgan Stanley is still cautious at Equal Weight and lowered its target slightly to $516, while BofA remains Neutral at $626. Net takeaway: Wall Street pros are broadly constructive on the long-term story, with several strong upside targets, but there is still a minority neutral camp. This is a favorable analyst backdrop overall.
